Alpha 2.0
Login Register
» Authors » E Davicioni

E Davicioni

Explore the profile of E Davicioni including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 14
Citations 413
Followers 0
Related Specialties
Oncology
Urology
Molecular Biology
Top 10 Co-Authors
F Y Feng
A E Ross
E M Schaeffer
N Erho
R J Karnes
R B Den
P T Tran
S G Zhao
F Feng
Y Liu
Published In
Prostate Cancer Prostatic Dis
Ann Oncol
Oncogene
Transplant Proc
Cell Death Differ
Affiliations
Soon will be listed here.
Recent Articles
1.
Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials
Dal Pra A, Ghadjar P, Ryu H, Proudfoot J, Hayoz S, Michalski J, et al.
Ann Oncol . 2025 Feb; PMID: 39986927
Background: The SAKK 09/10 trial randomized biochemically recurrent prostate cancer patients to salvage radiation 64 Gy versus 70 Gy, and the NRG/RTOG 0126 randomized intermediate-risk prostate cancer patients to definitive...
2.
Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer
Sutera P, Shetty A, Hakansson A, Van der Eecken K, Song Y, Liu Y, et al.
Ann Oncol . 2023 May; 34(7):605-614. PMID: 37164128
Background: Metastatic castration-sensitive prostate cancer (mCSPC) is commonly classified into high- and low-volume subgroups which have demonstrated differential biology, prognosis, and response to therapy. Timing of metastasis has similarly demonstrated...
3.
Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy - an ancillary study of the SAKK 09/10 randomized clinical trial
Dal Pra A, Ghadjar P, Hayoz S, Liu V, Spratt D, Thompson D, et al.
Ann Oncol . 2022 May; 33(9):950-958. PMID: 35636621
Background: The Decipher genomic classifier (GC) has shown to independently prognosticate outcomes in prostate cancer. The objective of this study was to validate the GC in a randomized phase III...
4.
Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial
Hamid A, Huang H, Wang V, Chen Y, Feng F, Den R, et al.
Ann Oncol . 2021 Jun; 32(9):1157-1166. PMID: 34129855
Background: The phase III CHAARTED trial established upfront androgen-deprivation therapy (ADT) plus docetaxel (D) as a standard for metastatic hormone-sensitive prostate cancer (mHSPC) based on meaningful improvement in overall survival...
5.
Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer
Nguyen P, Martin N, Choeurng V, Palmer-Aronsten B, Kolisnik T, Beard C, et al.
Prostate Cancer Prostatic Dis . 2017 Jan; 20(2):186-192. PMID: 28117383
Background: We examined the ability of a biopsy-based 22-marker genomic classifier (GC) to predict for distant metastases after radiation and a median of 6 months of androgen deprivation therapy (ADT)....
6.
Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality
Tse B, Volpert M, Ratther E, Stylianou N, Nouri M, McGowan K, et al.
Oncogene . 2017 Jan; 36(24):3417-3427. PMID: 28092670
Recent evidence has implicated the transmembrane co-receptor neuropilin-1 (NRP1) in cancer progression. Primarily known as a regulator of neuronal guidance and angiogenesis, NRP1 is also expressed in multiple human malignancies,...
7.
Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis
Benzon B, Zhao S, Haffner M, Takhar M, Erho N, Yousefi K, et al.
Prostate Cancer Prostatic Dis . 2016 Nov; 20(1):28-35. PMID: 27801901
Background: B7-H3 (CD276), part of the B7 superfamily of immune checkpoint molecules, has been shown to have an immunomodulatory role. Its regulation, receptor and mechanism of action remain unclear. B7-H3...
8.
Cell cycle-coupled expansion of AR activity promotes cancer progression
McNair C, Urbanucci A, Comstock C, Augello M, Goodwin J, Launchbury R, et al.
Oncogene . 2016 Sep; 36(12):1655-1668. PMID: 27669432
The androgen receptor (AR) is required for prostate cancer (PCa) survival and progression, and ablation of AR activity is the first line of therapeutic intervention for disseminated disease. While initially...
9.
Decipher correlation patterns post prostatectomy: initial experience from 2 342 prospective patients
Den R, Santiago-Jimenez M, Alter J, Schliekelman M, Wagner J, Renzulli Ii J, et al.
Prostate Cancer Prostatic Dis . 2016 Aug; 19(4):374-379. PMID: 27574020
Background: Currently, there are multiple commercially available RNA-based biomarkers that are Medicare approved and suggested for use by the National Comprehensive Cancer Network guidelines. There is uncertainty as to which...
10.
Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk
Ross A, Den R, Yousefi K, Trock B, Tosoian J, Davicioni E, et al.
Prostate Cancer Prostatic Dis . 2016 May; 19(3):277-82. PMID: 27136742
Background: To date, there have been no published trials examining the impact of salvage radiation therapy (SRT) in the post-operative setting for prostate cancer (PCa). We conducted a retrospective, comparative...